Official Title
A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PBI-0451 in Healthy Subjects.
Brief Summary

This is a phase 1, placebo-controlled, blinded, randomized, dose escalation study of PBI-0451 in healthy subjects. PBI-0451 is a new chemical entity and inhibitor of the main protease of coronaviruses, including the SARS-CoV-2 that causes COVID-19 disease. The study is designed to evaluate the safety, tolerability and pharmacokinetics of PBI-0451 after single and multiple ascending doses and also to explore drug-drug interaction potential of PBI-0451.

Detailed Description

Combined Three part, double blind, (sponsor open) study. Part 1: Single ascending dose study.
Part 2: Multiple ascending dose study. Part 3: Drug-drug interaction study.

Completed
COVID19

Drug: PBI-0451 Dose 1

Dose level 1 of PBI-0451
Other Name: PBI-0451

Drug: PBI-0451 Dose 2

Dose level 2 of PBI-0451
Other Name: PBI-0451

Drug: PBI-0451 Dose 3

Dose level 3 of PBI-0451
Other Name: PBI-0451

Drug: PBI-0451 Dose 4

Dose level 4 of PBI-0451
Other Name: PBI-0451

Drug: Ritonavir

Ritonavir will be co-administered with the study drug in Treatments J and K
Other Name: Norvir

Drug: Midazolam

Midazolam will be co-administered with the study drug in Treatment L

Drug: Placebo

Placebo to match

Drug: PBI-0451

Dose level of PBI-0451 with a projected exposure

Drug: PBI-0451 Dose 5

Dose level 5 of PBI-0451
Other Name: PBi-0451

Eligibility Criteria

Inclusion Criteria:

1. Non-smoking, healthy male or female subjects aged 18-59 years.

2. Body Mass Index (BMI) of ≥ 19.0 and ≤ 30.0 kg/m2.

3. 12-Lead electrocardiogram (ECG) evaluation without clinically significant
abnormalities.

4. Normal renal function, including having a creatinine clearance (CLcr) ≥90mL/min

5. Male subjects and female subjects of childbearing potential who engage in heterosexual
intercourse must agree to use protocol-specified method(s) of contraception.

6. Screening laboratory assessments must be without clinically significant abnormalities
as assessed by the investigator.

Exclusion Criteria:

1. Pregnant and lactating females

2. Have received any investigational drug (or vaccine) within the last 30 days prior to
study dosing.

3. Have a positive test result for HIV or HBsAg.

4. Have poor venous access that limits phlebotomy

5. Have taken any prescription medications or over-the-counter medications, including
herbal products and dietary supplements within 28 days prior to start of study.

6. Have been treated with systemic steroids, immunosuppressant therapies, or
chemotherapeutic agents within 3 months prior to Screening or is expected to receive
these agents during the study.

7. Have a history of lymphoma, leukemia, or any malignancy within the past 5 years except
for basal cell or squamous epithelial carcinomas of the skin that have been resected
with no evidence of metastatic disease for 3 years.

8. Have a history of significant drug sensitivity, cardiac disease, syncope,
palpitations, or unexplained dizziness, implanted defibrillator or pacemaker, liver
disease, severe peptic ulcer disease, gastroesophageal reflux disease and a medical or
surgical treatment that permanently altered gastric absorption.

9. Have received inactivated vaccinations within 4 weeks prior to randomization or
receive live vaccinations within 4 weeks of Screening.

10. Received the COVID-19 vaccine either within 7 days or have not completed the series of
required 2 doses.

11. Have a history of excessive alcohol use or other illicit drug use within 6 months of
screening.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: 59 Years
Countries
New Zealand
Locations

Auckland City Hospital
Auckland, New Zealand

Mark Marshall, Principal Investigator
New Zealand Clinical Research

Pardes Biosciences, Inc.
NCT Number
MeSH Terms
Ritonavir
Midazolam